Spectrum Pharmaceuticals to Provide an Update on Ozarelix in BPH on Tuesday, April 22, 2008

Spectrum Pharmaceuticals, Inc., (Nasdaq: SPPI) today announced that Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer, and other members of senior management, will host a conference call and webcast to provide an update on Ozarelix. Information on the Phase 2b trial will be issued via press release on Tuesday, April 22, 2008 prior to the call. Conference Call   Tuesday, April 22, 2008 @ 2:00 p.m. Eastern/11:00 a.m. Pacific Domestic: 800-638-4930, passcode 97325885 International: 617-614-3944, passcode 97325885   Webcast and replays: www.spectrumpharm.com.   Audio replays will be available through April 29, 2008. Domestic: 888-286-8010, passcode 68022697 International: 617-801-6888, passcode 68022697 About Spectrum Pharmaceuticals We are a biopharmaceutical company that acquires, develops and commercializes a diversified portfolio of drug products, with a focus on oncology, urology and other critical health challenges. Our strategy is comprised of the following four parts: acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products with a focus on oncology and urology; establishing a commercial organization for the drug products in our pipeline as they are approved; continuing to build a team with significant drug development and commercialization expertise in our areas of focus, and; leveraging the expertise of partners around the world in areas of manufacturing, development and commercialization to assist us in the execution of our strategy. For more information, please visit our website at www.spectrumpharm.com. Forward-looking statement – This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, our strategy, Spectrum's ability to identify, acquire, develop and commercialize its portfolio of drug candidates, the Company's promising pipeline and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in- license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. SPECTRUM PHARMACEUTICALS, INC. ™, TURNING INSIGHTS INTO HOPE™ and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners. © 2008 Spectrum Pharmaceuticals, Inc. All Rights Reserved